Evaluation of serum lidocaine/monoethylglycylxylidide concentration to assess shunt closure in dogs with extrahepatic portosystemic shunts

Nausikaa Devriendt1 | Gonçalo Serrano1 | Siska Croubels2 | Emmelie Stock3 | Eva Vandermeulen3 | Dominique Paepe1 | Jennifer von Luckner4 | Hilde de Rooster1

1Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
2Laboratory of Pharmacology and Toxicology, Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
3Department of Medical Imaging of Domestic Animals and Small Animal Orthopaedics, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium
4Tierärztliche Klinik für Kleintiere Norderstedt, Norderstedt, Germany

Correspondence
Nausikaa Devriendt, Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820 Merelbeke, Belgium.
Email: nausikaa.devriendt@ugent.be

Abstract

Background: Liver function tests do not always normalize despite successful attenuation of extrahepatic portosystemic shunts (EHPSS).

Objectives: Assess the lidocaine/monoethylglycylxylidide (MEGX) test to determine liver perfusion after EHPSS closure.

Animals: Twenty dogs with EHPSS.

Methods: A prospective cohort study was performed and all dogs were tested at diagnosis, 1, 3, and 6 months postoperatively. After collecting a baseline blood sample (T0), 1 mg/kg body weight of lidocaine was injected intravenously. Fifteen (T15) and 30 minutes (T30) later, blood was collected. Plasma concentrations of lidocaine and its metabolites MEGX and glycylxylidide (GX) were determined, using a high-performance liquid chromatography with electrospray ionization tandem mass spectrometry method. Three months postoperatively, transsplenic portal scintigraphy was performed to determine EHPSS closure.

Results: At T15, median MEGX concentrations were higher in dogs with closed EHPSS compared to diagnosis (33.73 ng/mL [21.11-66.44 ng/mL] vs 13.74 ng/mL [7.25-21.93 ng/mL]; P < .001), but were not different (12.28 ng/mL [10.62-23.17 ng/mL] vs 13.74 ng/mL [7.25-21.93 ng/mL]) in dogs with persistent shunting. Sensitivity to determine shunt closure for MEGX at T15 was 96.2% (95% confidence interval [CI]: 78.4-99.8) and specificity 82.8% (95% CI: 63.5-93.5).

Conclusions and Clinical Importance: The lidocaine/MEGX test is a promising, rapid, and noninvasive blood test that seems helpful to differentiate dogs with closed EHPSS and dogs with persistent shunting after gradual attenuation.

KEYWORDS
blood test, canine, liver dysfunction, vascular anomaly

Abbreviations: AUROC, area under the curve of receiver operating characteristics; CI, confidence interval; CTA, computed tomography angiography; EHPSS, extrahepatic portosystemic shunt; GX, glycylxylidide; LOD, limit of detection; LOQ, limit of quantification; MAPSS, multiple acquired portosystemic shunts; MEGX, monoethylglycylxylidide; PSS, portosystemic shunt; ROC, receiver operating characteristics; T0, blood sample at time zero (baseline); T15, blood sample 15 minutes after lidocaine injection; T30, blood sample 30 minutes after lidocaine injection; TSPS, transsplenic portal scintigraphy.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
1 | INTRODUCTION

Portosystemic shunts (PSS), in which an aberrant vessel causes blood to bypass the liver, are the most common congenital vascular anomalies affecting the liver in small animals. Surgical attenuation is regarded as the best treatment method, but it is unclear which surgical treatment provides the best long-term outcome. Gradual attenuation of extrahepatic portosystemic shunts (EHPSS) is commonly performed to allow the liver to gradually adapt to the increased blood flow, consequently reducing the risk of developing multiple acquired portosystemic shunts (MAPSS). Medical imaging techniques such as Doppler ultrasonography, computed tomography angiography (CTA), portovenography, or scintigraphy can be used to determine EHPSS closure. All these imaging techniques require specialized equipment, sedation, or anesthesia and well-trained people to obtain and interpret the images. Furthermore, normalization of liver function through increased liver perfusion rather than shunt occlusion is the goal of treatment. Commonly used liver function tests, such as measurement of blood ammonia concentration after feed withholding, ammonia tolerance test, and serum bile acids give false-negative as well as false-positive results after surgery. The measurement of protein C activity is a potentially useful test in dogs after surgical attenuation of PSS, yet, further research is warranted.

Lidocaine is a commonly used analgesic drug in small animals, which is metabolized in the liver by cytochrome P450 to monoethylglycylxylidide (MEGX) and subsequently to glycylxylidide (GX). In human medicine, the hepatic metabolism of lidocaine is used as a dynamic liver function test. As MEGX accurately reflects the severity of hepatic dysfunction, it is not only a valuable test for quantitative evaluation of the liver dysfunction but it is also used as a prognostic predictor of liver diseases in adults. Advantages of the use of lidocaine are its short elimination half-life and its high hepatic extraction ratio, that is blood flow dependent, making it an attractive candidate for assessment of liver function in dogs with EHPSS. The lidocaine/MEGX test has already been evaluated in healthy dogs and lidocaine and its metabolites are well tolerated and measurable in this species. This test seems to be promising to indicate hepatic function in small numbers of dogs undergoing partial hepatectomy and subsequent autotransplantation of liver tissue, dogs with experimentally induced liver fibrosis, and dogs that underwent ligation of a portal branche and portocaval anastomosis. Although dosages of up to 1.0 mg/kg can be safely used in healthy dogs, the tolerated dose might be far lower in dogs with portosystemic shunting. Experimental studies showed that doses of 1 to 1.5 mg/kg of lidocaine are well tolerated in dogs with hepatic dysfunction.

The objectives of the current study were to evaluate the potential of the lidocaine/MEGX test to determine liver perfusion, and thus indirectly shunt closure, in dogs with congenital EHPSS after gradual shunt attenuation.

2 | MATERIALS AND METHODS

2.1 | Animals

Twenty client-owned dogs with congenital EHPSS were prospectively enrolled in the study. The study was approved by the ethical (EC2014-179) and deontological committee (2015N03), and all owners signed an informed consent prior to inclusion of their dog.

In all dogs, a routine blood examination, including measurement of blood ammonia and serum bile acid concentrations after feed withholding, was performed at diagnosis. One or more medical imaging techniques (B-mode and Doppler ultrasonography, CTA, or trans-splenic portal scintigraphy [TSPS]) were performed to diagnose the EHPSS. Dogs were medically supported for minimally 4 weeks prior to surgery with a combination of a liver diet, lactulose, and metronidazole. Subsequently, all dogs underwent gradual attenuation of the EHPSS by either an ameroid constrictor or thin film banding, depending on the preference of the primary surgeon. The gradual attenuating device was placed as close as possible to the exit of the EHPSS in the systemic circulation; at the level of the omental foramen in dogs with a portocaval shunt, at the level of the peritoneal leaf of the diaphragm close to the exit of the left hepatic vein in dogs with a portophrenic shunt, and intrathoracically in dogs with a portoazygos shunt through a transdiaphragmatic approach as described previously. Medical therapy was continued until the first follow-up visit 1 month postoperatively. Based on the clinical signs, physical examination findings, and results of blood analyses, it was decided whether administration of lactulose, metronidazole, or both lactulose and metronidazole was continued. All dogs received diet designed to support dogs with liver dysfunction until the second follow-up visit, 3 months postoperatively, during which a TSPS was performed to determine EHPSS closure. Shunt fractions of <4.3% were considered normal. Dogs with a closed EHPSS and dogs that developed MAPSS had another follow-up visit 6 months postoperatively. Dogs with persistent shunting indicative of a patent EHPSS were offered a second surgery to completely close the EHPSS. In case TSPS was inconclusive, CTA was offered. Owners of dogs with a closed EHPSS were advised to gradually change to a standard diet. Dogs with persistent shunting that did not undergo a second surgery were advised to keep the dog life-long on a diet designed to support dogs with liver dysfunction alone or in combination with lactulose, metronidazole, or both lactulose and metronidazole depending on the clinical signs and the preference of the attending veterinarian. Dogs that underwent a second surgery had the same follow-up visits as after the first surgery.

2.2 | Lidocaine/MEGX test

The lidocaine/MEGX test was performed in all dogs at diagnosis and at 1, 3, and 6 months postoperatively. Owners were instructed to fast their dog for 12 hours prior to testing. A baseline blood sample (T0) was collected from the jugular vein, and subsequently a peripheral
venous catheter was placed to administer 1 mg/kg body weight of lidocaine (Xylocaine 2%, Aspen Pharma Trading Limited, Dublin, Ireland) followed by 1 mL of sterile saline. Additional venous blood samples were taken from the jugular vein 15 (T15) and 30 minutes (T30) after administration of lidocaine. All blood samples were collected in an EDTA tube and, after centrifugation at 3500g during 5 minutes, plasma was stored at −80°C until analysis in batch at the end of the study. Lidocaine, MEGX, and GX concentrations were measured using high-performance liquid chromatography with electrospray ionization tandem mass spectrometry as published earlier.28 A sample of 100 μL plasma was used for analysis. Limits of quantification (LOQ) of lidocaine, MEGX, and GX were .25, .50, and 2.5 ng/mL, respectively, and limits of detection ( LOD) were .08, .18, and .23 ng/mL, respectively.

2.3 | Statistical analyses

Statistical analyses were performed using SPSS Statistics 26 (IBM, Armonk, New York). Mann-Whitney U tests were used to evaluate differences between dogs with closed and persistent shunting between different metabolites (lidocaine, MEGX, and GX) at different sampling points (T15 and T30) and between different time points (diagnosis, 1, 3, and 6 months postoperatively). Kruskal-Wallis tests were performed separately in dogs with closed EHPSS and dogs with persistent shunting to evaluate the median concentrations of different metabolites at different sampling points over time. Multiple comparison tests with Bonferroni correction were performed in case statistical differences were present. Friedman 2-way analyses with Bonferroni correction were performed to assess the concentrations of different metabolites over time in dogs with closed EHPSS and dogs with persistent shunting. For dogs with closed EHPSS after the first surgery, all different time points were assessed, whereas for dogs that had persistent shunting after the first surgery, only data at diagnosis, 1, and 3 months were assessed.

A receiver operating characteristics (ROC) curve was plotted using values of EHPSS at diagnosis, 3, and 6 months postoperatively. The area under the curve of ROC (AUROC) was calculated with 90% confidence interval (CI) and optimal cutoff values were determined. Sensitivity and specificity to determine shunt closure postoperatively were calculated using 2 × 2 contingency tables and 95% CI were calculated.

3 | RESULTS

3.1 | Study samples

Twenty dogs with EHPSS were enrolled. Several breeds were represented (see Table S1). At diagnosis, median age was 7.5 months (range, 2-74 months) and median body weight was 3.8 kg (range, 1.5-8.4 kg). All information on individual age, body weight, breed, and sex are mentioned in Table S1. Surgical attenuation was performed using an ameroid constrictor in 15 dogs and thin film banding in 5 dogs. After the first surgery, 70% of dogs (n = 14) had a closed EHPSS, whereas 15% (n = 3) developed MAPSS. In all dogs in which MAPSS developed, surgical attenuation was performed using thin film banding. Two dogs had a persistent EHPSS: 1 after ameroid constrictor placement and the other 1 after thin film banding. Both dogs underwent a second surgery during which total ligation was performed, resulting in complete shunt closure and leading to a total closure ratio of 84% (16/19). In 1 dog in which an ameroid constrictor was placed, TSPS was inconclusive because of a poor-quality scan due to unclear reason. The owner of this dog refused further imaging as the dog was clinically doing very well; only data at diagnosis of this dog were used in statistical analysis. Postoperatively, median shunt fraction of dogs with closed EHPSS was 2.5% (1.0%-4.2%) and the median shunt fraction of dogs with persistent shunting was 86.5% (80.6%-96.0%). Not all dogs were represented for all follow-up visits. One dog with MAPSS was not represented for the 6-month follow-up visit and 1 dog with a closed EHPSS was not represented 3 months postoperatively and exceptionally had TSPS at the 6-month follow-up visit.

3.2 | Lidocaine/MEGX test

At T0, lidocaine and its metabolites were not detectable or <LOD. Based on median concentrations of different metabolites at different sampling points, the lidocaine/MEGX test could not differentiate at diagnosis nor at 1 month postoperatively between dogs that were going to have persistent shunting after surgery and dogs in which the EHPSS was going to be closed (Figure 1). At 3 and 6 months postoperatively, to the contrary, significant differences were present between median concentrations of different metabolites at different sampling points (T15 and T30) between dogs with closed EHPSS and dogs with persistent shunting (Figure 1). Friedman tests with post hoc analysis in dogs with closed EHPSS showed differences between diagnosis on the 1 hand and 1, 3, and 6 months postoperatively on the other hand, respectively, for concentrations of lidocaine at T30 (n = 11; P = .001, P = .001, and P = .001, respectively), MEGX at T15 (n = 10; P = .006, P < .001, and P = .006, respectively) GX at T15 (n = 10; P = .001, P < .001, and P = .001, respectively) and GX at T30 (n = 11; P = .005, P < .001, and P < .001, respectively). For MEGX at T30 significant differences were present between diagnosis and 3 and 6 months postoperatively (n = 11; P = .005 and p.048, respectively). In dogs with persistent EHPSS, no significant differences over time were present (n = 5 at T15 and n = 4 at T30).

For each metabolite at each sampling point, a ROC curve was plotted and 2 cutoff values were retained, 1 with optimal combination of sensitivity and specificity, and a second 1 with 100% sensitivity and the highest specificity possible (Table 1). For MEGX at T15, 100% sensitivity could not be reached.

3.3 | Adverse effects and missing data

No observable adverse effects occurred after administration of lidocaine. In 1 dog with an EHPSS that was closed after surgery, no
lidocaine, MEGX, nor GX was detected in any of the samples at diagnosis, so possibly lidocaine was inadvertently not administered to this dog. This dog was not included in the Friedman 2-way analysis to assess the concentrations of different metabolites over time. In 2 dogs, the sample T15 was not collected (both at 3 months postoperatively in dogs with closed EHPSS) and in 2 other dogs the sample T30 was not collected (1 at 1 month postoperatively in a dog with persistent shunting and the other at 6 months postoperatively in a dog with closed EHPSS), due to dogs not being cooperative or because of the presence of a hematoma at the jugular veins secondary to multiple venepunctures. Two dogs with a closed EHPSS feed was not withheld at the 6-month follow-up visit.

4 | DISCUSSION

Based on the results obtained in the current study, the lidocaine/MEGX test is a promising test to distinguish between dogs with a
TABLE 1  Sensitivity and specificity of the optimal cutoff value combining sensitivity and specificity (cutoff 1) and the cutoff value with 100% sensitivity and the highest specificity possible (cutoff 2) to differentiate dogs with closed extrahepatic portosystemic shunts from dogs with persistent shunting.

|                | Cutoff 1          | Cutoff 2          |
|----------------|-------------------|-------------------|
| **Lidocaine**  |                   |                   |
| T15 (AUROC 0.67 (90% CI: 0.55-0.79) |                   |
| Concentration (ng/mL) | 277.25            | 191.54            |
| Sensitivity (%)   | 96.2              | 100.0             |
| 95% CI           | (78.4-99.8)       | (84.0-100.0)      |
| Specificity (%)  | 37.9              | 10.3              |
| 95% CI           | (21.3-57.6)       | (2.7-28.5)        |
| T30 (AUROC 0.88 (90% CI: 0.80-0.95) |                   |
| Concentration (ng/mL) | 212.55            | 124.07            |
| Sensitivity (%)   | 88.5              | 100.0             |
| 95% CI           | (68.7-97.0)       | (74.0-100.0)      |
| Specificity (%)  | 80.0              | 20.0              |
| 95% CI           | (60.9-91.6)       | (8.4-39.1)        |
| **MEGX**        |                   |                   |
| T15 (AUROC 0.92 (90% CI: 0.84-0.99) |                   |
| Concentration (ng/mL) | 23.7              | NA                |
| Sensitivity (%)   | 96.2              | NA                |
| 95% CI           | (78.4-99.8)       | NA                |
| Specificity (%)  | 82.8              | NA                |
| 95% CI           | (63.5-93.5)       | NA                |
| T30 (AUROC 0.76 (90% CI: 0.65-0.87) |                   |
| Concentration (ng/mL) | 25.11             | 87.26             |
| Sensitivity (%)   | 73.1              | 100.0             |
| 95% CI           | (51.9-87.6)       | (84.0-100.0)      |
| Specificity (%)  | 80.0              | 3.3               |
| 95% CI           | (60.9-91.6)       | (0.2-19.1)        |
| **GX**          |                   |                   |
| T15 (AUROC .93 (90% CI: 0.87-0.99) |                   |
| Concentration (ng/mL) | 12.4              | 27.7              |
| Sensitivity (%)   | 88.5              | 100.0             |
| 95% CI           | (68.7-97.0)       | (84.0-100.0)      |
| Specificity (%)  | 96.6              | 44.8              |
| 95% CI           | (80.4-99.8)       | (27.0-64.0)       |
| T30 (AUROC 0.96 (90% CI: 0.92-0.99) |                   |
| Concentration (ng/mL) | 19.8              | 34.1              |
| Sensitivity (%)   | 84.6              | 100.0             |
| 95% CI           | (64.3-95.0)       | (84.0-100.0)      |
| Specificity (%)  | 96.7              | 7.0               |
| 95% CI           | (80.9-99.8)       | (50.4-84.6)       |

Abbreviations: AUROC, area under the curve of receiver operating characteristics; CI, confidence interval; GX, glycylxylidide; MEGX, monoethylglycylxylidide; NA, not applicable; T15, blood sample 15 minutes after lidocaine injection; T30, blood sample 30 minutes after lidocaine injection.

closed EHPSS and those with persistent shunting after surgical attenuation. The most promising metabolite to determine EHPSS closure after surgery is MEGX determined 15 minutes after lidocaine administration.

Currently, several liver function tests are available; however, a simple, rapid, cost-effective liver test that accurately determines shunt closure postoperatively is lacking. Based on the data of this study, taking 1 blood sample 15 minutes after administration of lidocaine gives adequate information with a sensitivity of 96.2% and specificity of 82.8%. This makes it a much faster test than the serum bile acid stimulation test which takes 2 hours to complete. In addition, the latter test is a sensitive test to diagnose PSS; yet, reported sensitivity and specificity to determine shunt closure 3 to 6 months postoperatively is 85% and 77% respectively, which appears inferior to the sensitivity obtained by MEGX measurement 15 minutes after lidocaine administration. Other liver function tests commonly used in the postoperative phase are measurement of blood ammonia concentration after feed withholding and ammonia tolerance test; the former having a sensitivity of 19% to 44% and specificity of 100%, the latter a sensitivity of 89%, and a specificity of 85%. Furthermore, care should be taken as the ammonia tolerance test can trigger hepatic encephalopathy in dogs with persistent shunting.

Data from this study show that by determining MEGX 15 minutes after intravenous administration of lidocaine, more than 80% of the dogs with persistent shunting were correctly identified, and only 4% of dogs with closed EHPSS had false positive results postoperatively. Hence, the lidocaine/MEGX test is currently the most sensitive blood test available to diagnose successful EHPSS closure 3 months after surgery. At an individual level, the increase in MEGX and GX concentrations already reached statistical significance as early as 1 month after gradual attenuation of EHPSS in dogs with closed EHPSS (while no evolution was observed in dogs with persistent shunting). However, statistical differences between the median concentrations of metabolites in dogs with closed EHPSS and those with persistent shunting were only detectable 3 months postoperatively. Although it has been suggested that ameroid constrictors close much earlier than 3 months postoperatively, it can be speculated that it takes longer than 1 month for cytochrome P450 in the liver to function optimally. Based on the results of this study, the lidocaine/MEGX test seems a promising adjuvant test in dogs that have normal ammonia concentrations after surgical attenuation. In dogs with increased ammonia concentrations it is advised to perform medical imaging to differentiate between dogs with a persistent EHPSS and those with MAPSS. In dogs with ammonia concentrations within normal limits and high MEGX concentrations at T15, the EHPSS is likely closed, and therefore additional medical imaging to determine shunt closure might not be of added value. Lidocaine has a high hepatic extraction ratio, which is a measure for the perfusion of the liver. Metabolism of lidocaine into MEGX and GX, on the contrary, gives information about the hepatic metabolism. In an experimental study in dogs that underwent ligation of 1 of the portal branches, dogs in which a portocaval anastomosis was created and dogs in which both 1 of the portal branches was ligated and a portocaval anastomosis was created, the lidocaine/
MEGX test was performed. Findings of this study suggest that MEGX reflects the function of mitochondria in the hepatic cells. In dogs with a congenital EHPSS, lidocaine clearance significantly increased after surgical attenuation in dogs with closed EHPSS, whereas no significant change in lidocaine concentrations over time could be detected in dogs with persistent shunting. Parallel findings were observed for MEGX and GX, indicating that not only the liver perfusion but also the hepatic metabolism improved significantly in dogs with closed EHPSS.

The lidocaine/MEGX test is currently used in human medicine and determination can be performed in several laboratories over the world. It is, however, important to keep in mind that the LOQ of the method to analyze dog plasma is required to be much lower compared to human plasma samples. Reference values of MEGX in healthy dogs 15 minutes after lidocaine administration are 34 to 79 ng/mL, which are about half of the reference values in human medicine, who receive the same dose of lidocaine. This is most likely due to a slower capacity for MEGX formation in dogs compared to people.

In order to perform a reliable lidocaine/MEGX test, lidocaine needs to be strictly administered intravenously, as extravasation might result in falsely decreased values. As a consequence, intravenous injection via a peripheral intravenous catheter is preferred over injection through a needle. More research is needed to determine how much influence it would have if blood samples are not taken exactly 15 minutes after lidocaine administration. Furthermore, it would be interesting to investigate the added value of GX in dogs that have MEGX concentrations that are close to the cutoff value and to determine the ideal timing after surgery to perform the lidocaine/MEGX test.

Lidocaine is a cheap and widely available analgesic drug that has a wide safety margin. Lidocaine in plasma is partially unbound (pharmacologically active fraction) and partially bound to plasma proteins (reservoir fraction). In healthy humans, 19.9% to 38.8% is unbound, 20% is bound to albumin and the remainder is bound to acute phase protein α-1 acid glycoprotein. Lidocaine has a high hepatic extraction ratio, with other organs, such as the kidneys eliminating only a small fraction.

For the lidocaine/MEGX test only a low dose of lidocaine (1 mg/kg) is needed and no adverse effects are anticipated. Yet, in order to ensure good test results, plasma needs to be separated and sent frozen to the laboratory. Previous studies have shown that hepatic encephalopathy in dogs with PSS is associated with an inflammatory state, in which acute phase proteins, such as C-reactive protein, are increased. It is unclear if α-1 acid glycoprotein, another marker of acute inflammation, is increased in dogs with EHPSS. Similar to the situation in humans where lidocaine is bound to α-1 acid glycoprotein, the amount of α-1 acid glycoprotein (and possibly other acute phase proteins) might also affect the bound fraction of lidocaine in dogs. An experimental study in rats with portocaval shunts, however, failed to detect an increase in α-1 acid glycoprotein 4 weeks after creation of the PSS. It is not known so far whether α-1 acid glycoprotein is increased in dogs with EHPSS. As the affinity for the cytochrome P enzymes is high for drugs with a high hepatic extraction ratio, both bound and unbound drugs will be metabolized. Consequently, an increased bound fraction of lidocaine decreases the pharmacologically active fraction, which, for the purpose of the lidocaine/MEGX test would be advantageous. Indeed, although previous studies and the present study have shown that the 1 mg/kg body weight dose of lidocaine is safe in dogs with liver dysfunction, this even further decreases the risk of potential toxicity of lidocaine, without affecting the outcome of the lidocaine/MEGX test. At this moment, it is unsure what the expected bound fraction of lidocaine in dogs with EHPSS is and if this would be different in dogs with overt versus mild hepatic encephalopathy.

As the activity of cytochrome P450 enzymes in the liver in humans is known to be dependent on genetic factors, age, sex, nutritional status, and drugs, individual variations in lidocaine metabolism are also to be expected in dogs. It has been described in healthy dogs that females have a higher concentration of MEGX 15 minutes after lidocaine administration than males; although this difference was no longer observed 30 minutes after lidocaine administration. In the same study, MEGX concentration was not influenced by the age of the dogs. In the current study, clear differences were not observed between dogs of different sexes nor ages. Statistical analyses could, however, not be performed due to the small number of dogs included.

Besides the promising results, this study has also several limitations. Although all owners were asked to keep their dog fasted for 12 hours, some dogs were not fasted and, hence, lipemic samples were obtained. Furthermore, as multiple blood samples were taken, some samples were hemolytic. The influence of lipemia and hemolysis was not investigated in this study; however, there were no indications that any of these factors had a clear impact on the results. It also needs to be mentioned that the length of the storage time between different samples varied greatly. As all samples were analyzed in batch, the oldest samples were frozen at −80°C during 3 years. Nevertheless, MEGX is reported to be a stable metabolite as multiple freeze-thaw cycles and storage at −20°C during 8 months did not change the concentration significantly. Furthermore, only a relatively small number of dogs was included, especially the number of dogs with persistent shunting was low. Additionally, some dogs were not presented for all follow-up visits and in other dogs, not all blood samples could be collected. Despite this limited cohort of dogs, statistical significance was reached. However, a 90% CI for the AUROC had to be used, in order for the CI interval to be within the normal range, which might imply that the CI is narrower than it actually is.

In conclusion, the lidocaine/MEGX test is an assay that shows promise to differentiate between dogs with closed EHPSS and dogs with persistent shunting after gradual attenuating surgery. It is a safe test that only takes 15 minutes to complete and is easy to perform. More investigations are, however, warranted in a larger cohort of dogs with PSS as well as other liver diseases to consolidate these promising results. Furthermore, the lidocaine/MEGX test should be tested in healthy dogs to establish accurate reference values and cutoff values.
ACKNOWLEDGMENT
Funding provided by Gesellschaft zur Förderung Kynologischer Forschung e.V. Preliminary results were presented at the online ECVIM-CA Congress 2020.

CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.

OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION
Approval: EC 2014/179; Deontological committee: 2015N03.

HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.

ORCID
Nausikka Devriendt https://orcid.org/0000-0002-5070-8176
Gonçalo Serrano https://orcid.org/0000-0002-0138-4064
Emmelie Stock https://orcid.org/0000-0002-9982-1532

REFERENCES
1. Broome CJ, Walsh VP, Braddock JA. Congenital portosystemic shunts in dogs and cats. N Z Vet J. 2004;52:154-162.
2. Greenhalgh SN, Reeve JA, Johnstone T, et al. Long-term survival and quality of life in dogs with clinical signs associated with a congenital portosystemic shunt after surgical or medical treatment. J Am Vet Med Assoc. 2014;245:527-533.
3. Serrano G, Charalambous M, Devriendt N, Rooster H, Mortier F, Paepke T. Treatment of congenital cava-azygous portosystemic shunts in dogs: a systematic review and meta-analysis. J Vet Intern Med. 2019;33:1865-1879.
4. Berent AC, Tobias KM. Portosystemic vascular anomalies. Vet Clin North Am Small Anim Pract. 2009;39:513-541.
5. Murphy ST, Ellison GW, Long M, van Gilder J. A comparison of the amiod condstrictor versus ligation in the surgical management of single extrahepatic portosystemic shunts. J Am Anim Hosp Assoc. 2001;37:390-396.
6. Burton CA, White RN. Portovenogram findings in cases of elevated bile acid concentrations following correction of portosystemic shunts. J Small Anim Pract. 2001;42:536-540.
7. Landon BP, Abraham LA, Charles JA. Use of transcolonic portal scintigraphy to evaluate efficacy of cellophane banding of congenital extrahepatic portosystemic shunts in 16 dogs. Austr Vet J. 2008;86:169-179.
8. Nelson NC, Nelson LL. Imaging and clinical outcomes in 20 dogs treated with thin film banding for extrahepatic portosystemic shunts. Vet Surg. 2016;45:736-745.
9. Schaub S, Hartmann A, Schwarz T, Kemper K, Pueckler KH, Schneider MA. Comparison of contrast-enhanced multidetector computed tomography angiography and splenopancreatography for the evaluation of portosystemic-shunt occlusion after cellophane banding in dogs. BMC Vet Res. 2016;12:283.
10. Szatmári V, Rothuizen J, van Sluijs FJ, et al. Ultrasonographic evaluation of partially attenuated congenital extrahepatic portosystemic shunts in 14 dogs. Vet Rec. 2004;155:448-456.
11. Vallarino N, Pil S, Devriendt N, et al. Diagnostic value of blood variables following attenuation of congenital extrahepatic portosystemic shunt in dogs. Vet Rec. 2019;187(7):e48. https://doi.org/10.1136/vr.105296.
12. van Straten G, Spee B, Rothuizen J, van Straten M, Favier RP. Diagnostic value of the rectal ammonia tolerance test, fasting plasma ammonia and fasting plasma bile acids for canine portosystemic shunting. Vet J. 2015;204:282-286.
13. Center SA. Hepatic vascular malformations in small dog breeds: what the textbooks don’t tell you. Proceedings of the Annual Conference of American Animal Hospital Association. Phoenix, AZ: American Animal Hospital Association; 2009:279-283.
14. Toulza O, Center SA, Brooks MB, Erb HN, Warner KL, Deal W. Evaluation of plasma protein C activity for detection of hepatobiliary disease and portosystemic shunting in dogs. J Am Vet Med Assoc. 2006;229:1761-1771.
15. Bill TJ, Clayman MA, Morgan RF, Gampfer TJ. Lidocaine metabolism pathophysiology, drug interactions, and surgical implications. Aesthet Surg J. 2004;24:307-311.
16. Ercolani G, Grazi GL, Callivìa R, et al. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery. Surgery. 2000;127:464-471.
17. Muñoz AE, Miguez C, Rubio M, et al. Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration. Dig Dis Sci. 1999;44:789-795.
18. Oellerich M, Raudé E, Burdelski M, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem. 1987;25:845-853.
19. Potter JM, Oellerich M. The use of lidocaine as a test of liver function in liver transplantation. Liver Transpl Surg. 1996;2:211-224.
20. Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol. 1993;19:140-147.
21. Neumann S, Frenz M, Streit F, Oellerich M. Formation of monoethylglycinexylidide (MEGX) in clinically healthy dogs. Can J Vet Res. 2011;75:317-320.
22. Pérez-Guille BE, Villegas-Alvarez F, Toledo-López A, et al. Pharmacokinetics of lidocaine and its metabolite as a hepatic function marker in dogs. Proc West Pharmacol Soc. 2011;54:62-65.
23. Feng YH, Hu XD, Zhai L, et al. Shear wave elastography results correlate with liver fibrosis histology and liver function reserve. World J Gastroenterol. 2016;22:4338-4344.
24. Matsuysama K, Fukuda Y, Miyake H, Yogita S, Tashiro S. Experimental study of the evaluation of liver function on the opposite side during portacaval anastomosis and ligation of the left portal branch. J Med Invest. 2004;51:84-95.
25. Lemo N, Vnuk D, Radjic B, Skender L, Karacic V, Bric D. Determination of the toxic dose of lidocaine in dogs and its corresponding serum concentration. Vet Rec. 2007;160:374-375.
26. Or M, Kitshoff A, Devriendt N, de Ridder M, Quist-Rybachuk G, de Rooster H. Transdiaphragmatic approach to attenuate portoozygotic shunts inserting in the thorax. Vet Surg. 2016;45:1013-1018.
27. Cole RC, Morandi F, Avenell J, Daniel GB. Trans-splenic portal scintigraphy in normal dogs. Vet Radiol Ultrasound. 2005;46:146-152.
28. Maes A, Weiland L, Sanderson C, et al. Determination of lidocaine and its two N-desethylated metabolites in dog and horse plasma by high-performance liquid chromatography combined with electrospray ionization tandem mass spectrometry. J Chromatogr B Anal Syst Biomed Life Sci. 2007;852:180-187.
29. Strombeck DR, Weiser MG, Kaneko JI. Hyperammonemia and hepatic encephalopathy in the dog. J Am Vet Med Assoc. 1975;166:1105-1108.
30. Mohl ML, Kyles AE, Hardie EM, et al. Evaluation of aminoid ring constrictors for treatment of single extrahepatic portosystemic shunts in dogs: 168 cases (1995-2001). J Am Vet Med Assoc. 2005;226:2020-2030.
31. Hunt GB, Culp WT, Mayhew KN, et al. Evaluation of in vivo behavior of aminoid ring constrictors in dogs with congenital extrahepatic...
portosystemic shunts using computed tomography. Vet Surg. 2014;43:834-842.

32. Feldman HS, Arthur GR, Covino BG. Comparative systemic toxicity of convulsant and superconvulsant doses of intravenous ropivacaine, bupivacaine, and lidocaine in the conscious dog. Anesth Analg. 1989;69:794-801.

33. Routledge PA, Barchowsky A, Bjornsson TD, Kitchell BB, Shand DG. Lidocaine plasma protein binding. Clin Pharmacol Ther. 1980;27:347-351.

34. Boyes RN, Scott DB, Jebson PB, et al. Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther. 1971;12:105-116.

35. Gow AG, Marques AI, Yool DA, et al. Dogs with congenital portosystemic shunting (cPSS) and hepatic encephalopathy have higher serum concentrations of C-reactive protein than asymptomatic dogs with cPSS. Metab Brain Dis. 2012;27:227-229.

36. Aller MA, Garcia-Fernández MI, Sánchez-Patán F, et al. Plasma redox status is impaired in the portacaval shunted rat – the risk of the reduced antioxidant ability. Comp Hepatol. 2008;7:1.

37. Yuki M, Itoh H, Takase K. Serum alpha-1-acid glycoprotein concentration in clinically healthy puppies and adult dogs and in dogs with various diseases. Vet Clin Pathol. 2010;39:65-71.

38. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet. 1984;9(Suppl 1):10-17.

39. ter Weijden E, van den Broek MPH, Ververs FFT. Easy and fast LC-MS/MS determination of lidocaine and MEGX in plasma for therapeutic drug monitoring in neonates with seizures. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;881-882:111-114.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Devriendt N, Serrano G, Croubels S, et al. Evaluation of serum lidocaine/monoethylglycylxylidide concentration to assess shunt closure in dogs with extrahepatic portosystemic shunts. J Vet Intern Med. 2021;35:261–268. https://doi.org/10.1111/jvim.16030